https://www.healthline.com/nutrition/what-is-tofu#isoflavones
Posts Tagged ‘dietandhealth’
Tofu: Nutrients, Benefits, Downsides, and More
August 27, 2023Comparing Sweeteners: Xylitol vs. Stevia
July 3, 2023What Is ‘Food Noise’? How Ozempic Quiets Obsessive Thinking About Food – The New York Times
June 25, 2023How to Get Rid of Bad Breath – The New York Times
June 25, 2023How to Eat Powdered Peanut Butter With Your Food
June 20, 2023Benefits of Aquaphor on Face – MyDCSI
May 15, 2023Wildfire smoke getting into your home? Build a DIY Corsi-Rosenthal air filter. » Yale Climate Connections
April 30, 2023A new class of drugs for weight loss could end obesity | The Economist
April 28, 2023https://www.economist.com/briefing/2023/03/02/a-new-class-of-drugs-for-weight-loss-could-end-obesity
GLP-1 agonists :
wegovy ozempic mounjaro
https://www.ncbi.nlm.nih.gov/books/NBK551568/#:~:text=Glucagon%2Dlike%20peptide%2D1%20agonists,and%20contraindications%20for%20these%20drugs. QT:{{”
Mechanism of Action
Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GIP), both incretin hormones inactivated by dipeptidyl peptidase-4 (DPP-4), stimulate insulin secretion after an oral glucose load via the incretin effect.[10][11] In type 2 diabetes, this process can become blunted or even be absent; however, the utilization of pharmacological levels of GLP-1 can revive insulin excretion. The benefits of this form of therapy to treat type 2 diabetes include delayed gastric emptying and inhibiting the production of glucagon from pancreatic alpha cells if blood sugar levels are high.
“}}
A new class of drugs for weight loss could end obesity | The Economist
April 28, 2023https://www.economist.com/briefing/2023/03/02/a-new-class-of-drugs-for-weight-loss-could-end-obesity
GLP-1 agonists :
wegovy ozempic mounjaro
QT:{{”
Mechanism of Action
Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GIP), both incretin hormones inactivated by dipeptidyl peptidase-4 (DPP-4), stimulate insulin secretion after an oral glucose load via the incretin effect.[10][11] In type 2 diabetes, this process can become blunted or even be absent; however, the utilization of pharmacological levels of GLP-1 can revive insulin excretion. The benefits of this form of therapy to treat type 2 diabetes include delayed gastric emptying and inhibiting the production of glucagon from pancreatic alpha cells if blood sugar levels are high.
“}}
linkstream2 microblog 